BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs

Summary

BlossomHill Therapeutics and Latigo Therapeutics completed oversubscribed IPOs on Nasdaq, raising $150 million and $345 million respectively. BlossomHill will fund Phase 1/2 development of a non-small cell lung cancer drug, while Latigo will advance its late-stage non-opioid pain medication.